MIM
NVAX icon

MetLife Investment Management’s Novavax NVAX Stock Holding History

MetLife Investment Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$645K Sell
79,221
-1,319
-2% -$12K ﹤0.01% 1629
2025
Q4 		$541K Sell
80,540
-10,570
-12% -$79.7K ﹤0.01% 1757
2025
Q3 		$790K Hold
91,110
– – ﹤0.01% 1585
2025
Q2 		$574K Buy
91,110
+2,078
+2% +$13.8K ﹤0.01% 1609
2025
Q1 		$571K Sell
89,032
-4,415
-5% -$36.5K ﹤0.01% 1664
2024
Q4 		$751K Buy
93,447
+11,725
+14% +$113K ﹤0.01% 1569
2024
Q3 		$1.03M Hold
81,722
– – 0.01% 1372
2024
Q2 		$1.03M Buy
81,722
+23,225
+40% +$234K 0.01% 1331
2024
Q1 		$280K Buy
58,497
+12,479
+27% +$57.9K ﹤0.01% 1997
2023
Q4 		$221K Hold
46,018
– – ﹤0.01% 2189
2023
Q3 		$333K Hold
46,018
– – ﹤0.01% 1878
2023
Q2 		$342K Buy
46,018
+40,816
+785% +$321K ﹤0.01% 1942
2023
Q1 		$36K Buy
5,202
+485
+10% +$4.46K ﹤0.01% 2738
2022
Q4 		$48.5K Sell
4,717
-124
-3% -$2.19K ﹤0.01% 2765
2022
Q3 		$88.1K Buy
4,841
+3
+0.1% +$130 ﹤0.01% 2711
2022
Q2 		$249K Sell
4,838
-39
-0.8% -$2.02K ﹤0.01% 2160
2022
Q1 		$359K Buy
+4,877
New +$435K ﹤0.01% 1985
2021
Q2 		– Sell
-22,592
Closed -$4.1M – 2470
2021
Q1 		$4.1M Sell
22,592
-1,954
-8% -$389K 0.04% 494
2020
Q4 		$2.74M Sell
24,546
-1,077
-4% -$114K 0.03% 671
2020
Q3 		$2.78M Hold
25,623
– – 0.03% 574
2020
Q2 		$2.14M Buy
25,623
+10,828
+73% +$414K 0.02% 686
2020
Q1 		$201K Buy
+14,795
New +$125K ﹤0.01% 1694
2019
Q1 		– Sell
-9,069
Closed -$334K – 2584
2018
Q4 		$334K Hold
9,069
– – ﹤0.01% 1613
2018
Q3 		$341K Sell
9,069
-237
-3% -$6.67K ﹤0.01% 1777
2018
Q2 		$249K Buy
9,306
+2,368
+34% +$80K ﹤0.01% 1818
2018
Q1 		$291K Hold
6,938
– – ﹤0.01% 1687
2017
Q4 		$172K Buy
+6,938
New +$169K ﹤0.01% 2006

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's NVAX Position: Q1 2026 in Review

MetLife Investment Management reduced its Novavax (NVAX) stake by 1.6% in Q1 2026, selling an estimated $12K and leaving 79,221 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

MetLife Investment Management first reported a position in NVAX in Q4 2017 and has held it in 27 quarters since. The position peaked at $4.1M in Q1 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • MetLife Investment Management held 79,221 shares of Novavax worth $645K as of Q1 2026.
  • MetLife Investment Management sold 1,319 Novavax shares in Q1 2026, an estimated $12K.
  • Novavax made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1629 holding.
  • MetLife Investment Management first reported a position in Novavax in Q4 2017 and has held it in 27 quarters since.
  • MetLife Investment Management's Novavax position peaked at $4.1M in Q1 2021.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.